Biomarkers, Effectiveness, and Safety of Aflibercept 8mg Modified Fixed Dose Regimen in Treatment-Naïve nAMD Patients

Clinical trial NCT07728981 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07728981
Sponsor: Tianjin Medical University Eye Hospital
Status: NOT_YET_RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD

Start date: 2026-07-25
Primary completion: 2026-08-15
Enrollment: 49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.